Dolutegravir: First Global Approval

S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges

(2016) Johannes Carl Christoph Lenz et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Dolutegravir in antiretroviral-naive adults with HIV-1

(2013) Hans-Jürgen Stellbrink et al.   AIDS

Prevalent Polymorphisms in Wild-Type HIV-1 Integrase Are Unlikely To Engender Drug Resistance to Dolutegravir (S/GSK1349572)

(2013) Cindy Vavro et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans

(2013) Stephen Castellino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

(2013) Michael E. Abram et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Next-Generation Integrase Inhibitors

(2013) Sharon L. Karmon et al.   DRUGS

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

(2013) Pedro Cahn et al.   LANCET

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

(2013) Francois Raffi et al.   LANCET

Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis

(2013) Peter Messiaen et al.   PLoS One

Emerging patterns and implications of HIV-1 integrase inhibitor resistance

(2012) Anna Maria Geretti et al.   CURRENT OPINION IN INFECTIOUS DISEASES

HIV-1 Antiretroviral Resistance

(2012) Michele W. Tang et al.   DRUGS

The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults

(2012) Mark R. Underwood et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

(2012) Kelly E. Dooley et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of a Single Supratherapeutic Dose of Dolutegravir on Cardiac Repolarization

(2012) Shuguang Chen et al.   PHARMACOTHERAPY

Resistance to HIV integrase inhibitors

(2012) Thibault Mesplède et al.   Current Opinion in HIV and AIDS

The development of novel HIV integrase inhibitors and the problem of drug resistance

(2012) Mark A Wainberg et al.   Current Opinion in Virology

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS

Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of Dolutegravir

(2011) Ivy Song et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

(2011) Ivy Song et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572

(2011) Ivy Song et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers

(2011) P. Patel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

(2011) Jan van Lunzen et al.   LANCET INFECTIOUS DISEASES

Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy Subjects

(2010) Ivy Song et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Integrase inhibitors in the treatment of HIV-1 infection

(2010) W. G. Powderly   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy Participants

(2010) Ivy Song et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

(2009) S. Min et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY